← Back to home

Refractory B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic HL

Clinical trials for Refractory B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic HL explained in plain language.

Never miss a new study

Get alerted when new Refractory B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic HL trials appear

Sign up with your email to follow new studies for Refractory B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic HL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New combo tackles tough lymphomas

Disease control Ongoing

This early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorin…

Matched conditions: REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DLBCL AND CLASSIC HL

Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control

Last updated Aug 23, 2026 00:00 UTC

Refractory B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic HL

Get alerted when new Refractory B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic HL trials appear

New combo tackles tough lymphomas